Navigation Links
Syndexa Pharmaceuticals Corporation and ChemDiv, Inc. Announce Discovery Collaboration
Date:4/28/2008

SAN DIEGO and CAMBRIDGE, Mass., April 28 /PRNewswire/ -- ChemDiv, Inc., a global CRO for drug discovery & development, and Syndexa Pharmaceuticals Corporation, a biopharmaceutical company developing first-in-class drugs for the treatment of metabolic diseases, have announced today the signing of a collaborative discovery research agreement. Under the terms of the agreement, ChemDiv will discover small molecule ligands for biotargets nominated by Syndexa. Financial terms of the collaboration were not disclosed.

"We are very excited to deploy our discovery resources in this collaboration with Syndexa," said Dr. Ilya Okun, VP of Biology & CTO at ChemDiv, Inc. "ChemDiv's flexible service capabilities emphasize delivery of rapid, high-value results for our partners' drug discovery programs. We are able to realize that goal through the creative integration of the chemistry and biology components of our Discovery outSource(TM) platform."

"We are extremely pleased to be working with ChemDiv, a drug discovery partner with a strong track record. The collaboration will provide us with access to high quality screening capabilities and compound library resources. We anticipate that this project will accomplish our goal of discovering promising drug leads to enhance our R&D pipeline," said Teo Uysal, President and CEO, Syndexa Pharmaceuticals.

About ChemDiv, Inc.:

ChemDiv, Inc. (Chemical Diversity) is a global CRO delivering discovery opportunities and services for life science partners. ChemDiv is merging industrial and academic efforts to bring new approaches to the treatment of life-threatening diseases. Drawing on a long heritage in small-molecule chemistry research, a dedicated and personal approach to collaborative research and development as well as world class personnel and physical resources, ChemDiv provides partners with access to Discovery outSource(TM) a full service drug discovery offering encompassing synthetic chemistry; medicinal chemistry, diverse & focused screening libraries, global logistics and wide range of biology services for pre-clinical discovery & development projects. http://www.chemdiv.com

About Syndexa Pharmaceuticals Corporation:

Syndexa is engaged in the discovery and development of a new generation of small-molecule drugs that target the biological interface between inflammatory and metabolic pathways, and provide a novel mechanism for the treatment and prevention of metabolic diseases including obesity, type 2 diabetes and atherosclerosis. Syndexa's current programs include the development of inhibitors of obesity-induced Endoplasmic Reticulum (ER) stress and c-jun N-terminal kinase (JNK). Founded by leading scientists from Harvard and University of California, San Diego, the company is executing on its business strategy to rapidly build and commercialize a portfolio of breakthrough products. The company is headquartered in Cambridge, MA. For additional information, please visit http://www.syndexa.com.


'/>"/>
SOURCE ChemDiv, Inc.; Syndexa Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Aida Pharmaceuticals, Inc. Announces Update on Progress of Rh-Apo2L Testing
2. Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast
3. Keryx Biopharmaceuticals Receives Nasdaq Notification
4. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
5. Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
6. Aida Pharmaceuticals, Inc. Announces Completion of Research Institute Acquisition
7. Anadys Pharmaceuticals to Report First Quarter 2008 Financial Results
8. New Fragment-based Drug Discovery Platform Announced Between IOTA Pharmaceuticals Ltd, Cambridge (UK), and Beactica AB, Uppsala (Sweden)
9. MacroChem Acquires Virium Pharmaceuticals
10. GlaxoSmithKline to Acquire Sirtris Pharmaceuticals, a World Leader in Sirtuin Research and Development
11. Rib-X Pharmaceuticals to Present at Cambridge Healthtech Institutes 2nd Annual Challenge of Antibacterial Development Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... OR (PRWEB) , ... January 18, 2017 , ... ... that provide essential device-to-computer interconnect using USB or PCI Express, announced the ZEM5310 ... Cyclone V E FPGA into a compact business-card sized form factor suitable for ...
(Date:1/18/2017)... Jan. 18, 2017 Applied BioMath ( ... to drug research and development, today announced that ... and CEO of Applied BioMath, will present at ... Modeling (BAGIM) Meeting on Thursday January 19, 2017 ... , MA.   Dr. Burke,s talk "Quantitative Modeling ...
(Date:1/18/2017)... ... January 18, 2017 , ... Total ... successfully implanted SpineFrontier’s A-CIFT™ Solofuse-P™. The operation took place on Wednesday, January 11, ... The procedure was an anterior cervical discectomy and fusion on a 42 year ...
(Date:1/18/2017)... ... January 18, 2017 , ... MYOLYN, ... that it has submitted a 510(k) to the FDA, requesting clearance of the ... functional electrical stimulation (FES) technology. , The submission marks a major milestone ...
Breaking Biology Technology:
(Date:12/20/2016)... LONDON , Dec. 20, 2016 ... car sharing, rental and leasing is stoking significant ... of radio frequency technology, Bluetooth low energy (BLE), ... emerge as the next wave of wireless technologies ... vehicle access system to advanced access systems opens ...
(Date:12/19/2016)... y TORONTO , 19 de diciembre de 2016 ... Inc. que permitirá el desarrollo acelerado de MSC-1, un anticuerpo humanizado ... tipos de tumor en 2017, con múltiples sitios previstos a lo ... ... objetivo en el factor inhibidor de leucemia (LIF), una citoquina pleiotrópica ...
(Date:12/16/2016)... , Dec 16, 2016 Research and ... System Market - Global Forecast to 2021" report to their ... The ... to grow at a CAGR of 14.06% from 2016 to 2021. ... and is projected to reach 854.8 Million by 2021. The growth ...
Breaking Biology News(10 mins):